Can drug combo before surgery boost ovarian cancer outcomes?
NCT ID NCT04644289
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether giving the drugs olaparib (Lynparza) alone or combined with durvalumab (Imfinzi) before surgery is feasible and safe for people with advanced ovarian cancer. About 60 participants will receive the drugs for a short time before their planned tumor-removal surgery. The main goal is to see if the treatment can be completed without delays or major side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
olaparib (Lynparza) and durvalumab (Imfinzi)
What this could lead to
If successful, this could show that giving these drugs before surgery is a safe and practical way to shrink tumors, potentially improving surgical outcomes for ovarian cancer.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The drugs can cause side effects, and there is a risk of treatment delaying surgery or not working as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité Berlin, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie
RECRUITINGBerlin, State of Berlin, 13353, Germany
Contact
Contact
-
KEM Essen | Evang. Kliniken Essen Mitte
RECRUITINGEssen, North Rine-Westphalia, 45136, Germany
Contact
Contact
-
Klinikum rechts der Isar, Technische Universität München, Klinik und Poliklinik für Frauenheilkunde
RECRUITINGMünchen, Bavaria, 81675, Germany
Contact
Contact
-
Mammazentrum HH am Krankenhaus Jerusalem, Gynäkologisches Operationszentrum Hamburg
RECRUITINGHamburg, Free and Hanseatic City of Hamburg, 20357, Germany
Contact
Contact
-
Universitätsklinikum Carl Gustav Carus Dresden an der technischen Universität Dresden, Gynäkologisches Krebszentrum und Regionales Brustzentrum Dresden am Universitäts-KrebsCentrum
RECRUITINGDresden, Saxony, 01307, Germany
Contact
Contact
-
Universitätsklinikum Mannheim GmbH, Frauenklinik
RECRUITINGMannheim, Baden-Wurttemberg, 68167, Germany
Contact
Contact